



GNI Receives Patent Approval in China for Important Cancer Targets

Tokyo, October 25, 2007 – GNI Ltd, a leading biopharmaceutical company in Japan and China, is pleased to announce that China's Patent & Trademark Office has granted GNI regional rights for three PCT patents known as ULBP4, ULBP5, and ULBP9/10 (China Patents ZL 02828432.1, ZL 02829568.4, ZL 03826049.4). The patents cover a family of cancer-related genes/proteins used in cancer therapy and diagnosis and significantly enhance GNI's intellectual property portfolio.

The levels of ULBP proteins are frequently elevated in a variety of human cancers, including colon, stomach, liver, and lung cancers. These cancer-associated proteins can be recognized and attacked by immune cells in the body, an important process of immune surveillance against cancers. In addition, some of these proteins can be detected in cancer patients' blood samples. Therefore, identification of these cancer proteins may allow GNI researchers to develop novel targeted therapies or highly sensitive diagnostic assays for certain types of cancers.

Dr. Jun Wu, Chief Scientific Officer of GNI, said, "Our cancer research program has made steady progress in the last six years, which has been documented in our recent scientific publications. We will continue to focus on discovering interesting drug targets in-house to identify novel diagnostics and therapies."

For further inquiries

Tetsuya Yoshikawa in Japan Tel: +81 (03) 3580-0751

Ying Luo in China Tel: +86 1381-769-8961

About GNI

Founded in 2001, GNI is a clinical-stage international drug development company with its headquarters in Japan and major operations in China. GNI has successfully mapped gene regulatory networks via a complex process of reverse-engineering. Furthermore, GNI has developed the technology required to apply this data to drug development and discovery. In June 2005, GNI acquired Shanghai Genomics, which operates an integrated drug discovery and development platform in Shanghai, China. The combined strength of GNI and Shanghai Genomics has resulted in research collaborations with major international pharmaceutical companies. In August 2007 GNI was listed on the Mothers market of the Tokyo Stock Exchange (ticker symbol: 2160). For further information, please visit www.gene-networks.com and www.shanghaigenomics.com.

This press release contains "forward-looking" statements, including statements related to GNI's plans to pursue development of product candidates and the timing thereof. Any statements contained in this press release that are not statements of historical fact may be deemed to be forward-looking statements. Words such as "continue," "could," "may," and similar expressions are intended to identify these forward-looking statements. There are a number of important factors that could cause GNI's results to differ materially from those indicated by these forward-looking statements, including risks associated with the timing and success of clinical trials and the commercialization of product candidates. GNI does not undertake any obligation to update forward-looking statements.